Research

Home/Research

TargetCancer Foundation Announces Rare Cancer Precision Medicine Research Initiative

TargetCancer Foundation (TCF) proudly announced today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial that brings advances in precision medicine to people living with rare cancers and their treating physicians, right in their own communities.

By |2020-08-12T08:14:47-04:00August 12th, 2020|News, Research|

RARE Partnership in Advocacy, Funding, and Research for Gastrointestinal Stromal Tumor

Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.

By |2020-07-15T14:11:15-04:00July 14th, 2020|Advocacy, News, Research, SDH-Deficient GIST|

Life Raft Group Contributes Abstracts for ASCO

Although the ASCO (American Society for Clinical Oncology) will be a virtual meeting this year, The Life Raft Group continues to be at the forefront in collaborating in efforts to improve treatment for cancer patients. This year, two important abstracts will be presented online that illustrate these efforts.

By |2020-07-02T11:02:32-04:00May 13th, 2020|News, Research|

Dr. Gina D’Amato, GIST Specialist, Talks Advances in Sarcoma

In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.

By |2020-05-01T11:40:35-04:00May 1st, 2020|Mutational Testing, News, Research|

Science Forum Convened to Better Understand the State of GIST Research

As research regarding GIST and other relevant topics is extensive and dynamic, consensus among the Real World Evidence Team was that it would be a good idea to convene a group tasked with monitoring and assessing this research. Recently the LRG held its inaugural virtual meeting of the newly formed LRG Science Forum.

By |2020-04-28T15:55:34-04:00April 28th, 2020|News, Newsletter, Research|

Survival in Advanced GIST Has Improved Over Time – LRG Science

In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.

By |2020-05-01T10:01:32-04:00April 1st, 2020|Drug Treatment, LRG Science, News, Research|

Partnership for Survival – Treating the Rarest of the Rare

Our Rare Disease Day offering is a whitepaper titled 'Partnership for Survival – Treating the Rarest of the Rare' detailing how a collaboration with the NIH has become a model for other advocacy groups and researchers.

By |2020-02-28T14:30:39-05:00February 27th, 2020|Advocacy, News, Research|
Go to Top